A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults
- 17 November 2015
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (3), 337-344
- https://doi.org/10.2337/dc15-1111
Abstract
OBJECTIVE With rising obesity, it is becoming increasingly difficult to distinguish between type 1 diabetes (T1D) and type 2 diabetes (T2D) in young adults. There has been substantial recent progress in identifying the contribution of common genetic variants to T1D and T2D. We aimed to determine whether a score generated from common genetic variants could be used to discriminate between T1D and T2D and also to predict severe insulin deficiency in young adults with diabetes. RESEARCH DESIGN AND METHODS We developed genetic risk scores (GRSs) from published T1D- and T2D-associated variants. We first tested whether the scores could distinguish clinically defined T1D and T2D from the Wellcome Trust Case Control Consortium (WTCCC) (n = 3,887). We then assessed whether the T1D GRS correctly classified young adults (diagnosed at 20–40 years of age, the age-group with the most diagnostic difficulty in clinical practice; n = 223) who progressed to severe insulin deficiency RESULTS In the WTCCC, the T1D GRS, based on 30 T1D-associated risk variants, was highly discriminative of T1D and T2D (area under the curve [AUC] 0.88 [95% CI 0.87–0.89]; P < 0.0001), and the T2D GRS added little discrimination (AUC 0.89). A T1D GRS >0.280 (>50th centile in those with T1D) is indicative of T1D (50% sensitivity, 95% specificity). A low T1D GRS (P < 0.0001). T1D GRS, autoantibody status, and clinical features were independent and additive predictors of severe insulin deficiency (combined AUC 0.96 [95% CI 0.94–0.99]; P < 0.0001). CONCLUSIONS A T1D GRS can accurately identify young adults with diabetes who will require insulin treatment. This will be an important addition to correctly classifying individuals with diabetes when clinical features and autoimmune markers are equivocal.Keywords
Funding Information
- Diabetes UK
- National Institute for Health Research
- Wellcome Trust
This publication has 39 references indexed in Scilit:
- The clinical utility of C‐peptide measurement in the care of patients with diabetesDiabetic Medicine, 2013
- Imputing Amino Acid Polymorphisms in Human Leukocyte AntigensPLOS ONE, 2013
- Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetesNature Genetics, 2012
- The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetesDiabetologia, 2012
- Five Years of GWAS DiscoveryAmerican Journal of Human Genetics, 2012
- Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested modelsStatistics in Medicine, 2011
- Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetesNature Genetics, 2009
- Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA‐B and HLA‐ADiabetes, Obesity and Metabolism, 2009
- Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetesNature Genetics, 2008
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007